6 months trastuzumab non-inferior to 12 months for her2 positive early breast cancer
Published 3 years ago • 1.2K plays • Length 6:42Download video MP4
Download video MP3
Similar videos
-
4:04
the persephone trial: 6 months and 12 months of trastuzumab in breast cancer
-
1:56
persephone: 6 vs. 12-month adjuvant trastuzumab in early breast cancer
-
3:06
trastuzumab deruxtecan effective against brain metastases in her2-positive breast cancer
-
5:46
adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for her2-positive breast cancer
-
10:05
piii trial supports current standard 12-month adjuvant trastuzumab for her2-positive breast cancer
-
3:50
update from kaitlin for high-risk her2-positive early breast cancer
-
11:04
shorther trastuzumab treatment of her2 breast cancer: 9 weeks v 1 year
-
1:00
case study - 21 "breast cancer: causes, symptoms, and treatment l common cancer in women."
-
7:40
adjuvant trastuzumab did not improve outcomes for patients with her2-low breast cancer
-
6:47
extended adjuvant therapy for her2-positive early breast cancer
-
8:16
apt for her2 breast cancer patients with small tumours
-
7:44
treatment options for her2 breast cancer: a comprehensive guide
-
4:03
trastuzumab deruxtecan significantly improves pfs in breast cancer patients previously treated w...
-
7:31
adding lapatinib to adjuvant trastuzumab doesn't improve outcomes in her2-positive breast cancer
-
9:13
substituting trastuzumab emtansine for adjuvant trastuzumab improved idfs for breast cancer pati...
-
2:03
efficacy results for trastuzumab in her2-positive uterine serous carcinoma
-
5:42
updates on managing her2-positive early breast cancer
-
5:29
adding lapatinib to adjuvant trastuzumab doesn't improve outcomes in her2-positive breast cancer
-
47:29
optimizing therapy in her2 disease with dr. reshma mahtani